Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure.

Cardiovascular Drugs and Therapy
T Barry LevineJalal K Ghali

Abstract

Dronedarone is a novel multichannel blocker with antiadrenergic and vasodilatory properties. The aim of this study was to investigate the effects of dronedarone on functional capacity in patients with severe left ventricular (LV) dysfunction and compensated stable heart failure (HF). This was a multicentre, double-blind, randomized, placebo-controlled, dose-escalating study. Patients in sinus rhythm with impaired LV function (LV ejection fraction [LVEF] ≤ 30%) and compensated HF (New York Heart Association [NYHA] class I-II), who would continue to receive cardiovascular treatment (excluding antiarrhythmic agents), were eligible. A total of 124 patients were randomized to receive dronedarone (400 mg or 800 mg once daily or 600 mg twice daily) or placebo for 30 days. The primary objective was assessment of the effects of dronedarone on functional capacity, using the 6 min walk test. Secondary objectives included the effects of dronedarone on LVEF, cardiothoracic ratio, NYHA status, and Holter parameters. A total of 111 patients completed the study. There were no significant differences between dronedarone and placebo with respect to walking distance and LVEF. The cardiothoracic ratio was similar in all treatment groups throughout...Continue Reading

References

Aug 1, 1991·Stroke; a Journal of Cerebral Circulation·P A WolfW B Kannel
Mar 8, 1986·British Medical Journal·D P LipkinP A Poole-Wilson
Aug 16, 2003·European Heart Journal·Paul TouboulStefan H Hohnloser
Apr 20, 2005·Journal international de bioéthique = International journal of bioethics·UNKNOWN World Medical Association General Assembly
Mar 17, 2006·Drugs of Today·Karolina M Zareba
Jan 25, 2007·Expert Opinion on Investigational Drugs·Kristen K Patton, Richard L Page
Mar 29, 2007·The Annals of Pharmacotherapy·Krista M Dale, C Michael White
Aug 28, 2007·Journal of the American College of Cardiology·Kim FoxUNKNOWN Heart Rate Working Group
Sep 7, 2007·The New England Journal of Medicine·Bramah N SinghUNKNOWN EURIDIS and ADONIS Investigators
Jun 21, 2008·The New England Journal of Medicine·Lars KøberUNKNOWN Dronedarone Study Group
Feb 14, 2009·The New England Journal of Medicine·Stefan H HohnloserUNKNOWN ATHENA Investigators
May 1, 2009·The New England Journal of Medicine·Peter J Zimetbaum
Nov 6, 2009·Journal of the Indian Medical Association·UNKNOWN World Medical Association Inc

❮ Previous
Next ❯

Citations

Nov 16, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN PALLAS Investigators
Mar 20, 2012·Expert Opinion on Pharmacotherapy·Sheila A Doggrell, Jules C Hancox
Dec 20, 2012·The Annals of Pharmacotherapy·James M HollandsAndrew M Kates

❮ Previous
Next ❯

Software Mentioned

SAS
ATHENA
ERATO

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.